癌症相关疲劳（CRF）是多种癌症患者中最常见的并发症之一，严重影响患者的生活质量。然而，目前对于CRF综合症仅存在一些缓解症状的辅助疗法，缺乏对于其有效的药物治疗方法。二氯乙酸（DCA）作为丙酮酸脱氢酶激酶的小分子抑制剂，已被测试作为一种潜在的治疗方法，主要是基于其体外阻止细胞分裂的效果。我们发现，虽然DCA对两种小鼠癌症模型的肿瘤生长速率或标准癌症治疗（免疫疗法和化疗）的疗效没有影响，但是DCA通过降低循环乳酸浓度，在晚期肿瘤小鼠中保持了身体功能。体内液相色谱质谱/质谱研究表明，DCA治疗可能保持了细胞膜电位，推迟了蛋白质降解，并缓解了肿瘤携带小鼠肌肉中的氧化应激。总的来说，本研究为DCA作为治疗CRF小鼠模型中维持身体功能和动机的新型药物治疗提供了证据。

Cancer-related fatigue (CRF) is one of the most common complications in patients with multiple cancer types and severely affects patients' quality of life. However, there have only been single symptom-relieving adjuvant therapies but no effective pharmaceutical treatment for the CRF syndrome. Dichloroacetate (DCA), a small-molecule inhibitor of pyruvate dehydrogenase kinase, has been tested as a potential therapy to slow tumor growth, based largely on its effects in vitro to halt cell division. We found that although DCA did not affect rates of tumor growth or the efficacy of standard cancer treatment (immunotherapy and chemotherapy) in two murine cancer models, DCA preserved physical function in mice with late-stage tumors by reducing circulating lactate concentrations. In vivo liquid chromatography-mass spectrometry/mass spectrometry studies suggest that DCA treatment may preserve membrane potential, postpone proteolysis, and relieve oxidative stress in muscle of tumor-bearing mice. In all, this study provides evidence for DCA as a novel pharmaceutical treatment to maintain physical function and motivation in murine models of CRF.